Payment overview · 2025
General Payments
$6,216.05
241 reported records · 45 companies
Healthcare provider profile · identity verified
Prashant R Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · STUART, FL · NPI 1336135102
Verified facts
What the public records show
CMS Open Payments records show Prashant R Patel, MD received $6,216.05 in general payments during 2025 across 241 reported records.
Novartis Pharmaceuticals Corporation accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 75 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Inlyta, Jakafi, Keytruda, Lupron Depot, Nubeqa, Orgovyx, Venclexta, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lupron Depot by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Venclexta by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 29 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Orgovyx by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Xtandi by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nubeqa as an associated drug or biological on 24369 records involving 9557 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nubeqa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPDIVO as an associated drug or biological on 1605 records involving 1197 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Opdivo by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Pomalyst by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPDIVO as an associated drug or biological on 20448 records involving 6494 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Opdivo by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Sprycel by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tecentriq as an associated drug or biological on 3585 records involving 2526 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tecentriq by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Venclexta by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEYTRUDA as an associated drug or biological on 46588 records involving 15767 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Keytruda by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Promacta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INLYTA as an associated drug or biological on 2646 records involving 1964 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Inlyta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 16373 records involving 6981 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Orgovyx by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $1,251.02 | 20.1% | 22 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $580.22 | 9.3% | 29 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $542.57 | 8.7% | 35 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $352.75 | 5.7% | 17 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $343.00 | 5.5% | 8 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $321.10 | 5.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $304.39 | 4.9% | 17 | 2025 |
| SEAGEN INC. | Unresolved — no canonical attribution shown | $274.93 | 4.4% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $219.61 | 3.5% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $173.44 | 2.8% | 7 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $162.33 | 2.6% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151.45 | 2.4% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $144.60 | 2.3% | 6 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $102.30 | 1.6% | 4 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $100.58 | 1.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.22 | 1.5% | 4 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $92.22 | 1.5% | 4 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $86.81 | 1.4% | 4 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $75.92 | 1.2% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $70.79 | 1.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.67 | 1.1% | 3 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $63.97 | 1.0% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $48.02 | 0.8% | 2 | 2025 |
| Elekta, Inc. | Unresolved — no canonical attribution shown | $46.78 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.06 | 0.7% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $41.84 | 0.7% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $37.92 | 0.6% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $36.69 | 0.6% | 2 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $34.44 | 0.6% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $28.40 | 0.5% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $26.56 | 0.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.38 | 0.4% | 1 | 2025 |
| Biocon Biologics Inc | Unresolved — no canonical attribution shown | $23.74 | 0.4% | 1 | 2025 |
| Fennec Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.42 | 0.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.69 | 0.4% | 1 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $22.68 | 0.4% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $22.54 | 0.4% | 1 | 2025 |
| Spectrum Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.41 | 0.4% | 1 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $21.70 | 0.3% | 1 | 2025 |
| Menarini Silicon Biosystems, Inc. | Unresolved — no canonical attribution shown | $21.15 | 0.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.73 | 0.3% | 1 | 2025 |
| ACCORD HEALTHCARE, INC. | Unresolved — no canonical attribution shown | $19.54 | 0.3% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.09 | 0.3% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $16.46 | 0.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.92 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,504.82 | 223 |
| Long term medical supply or device loan | $1,080.33 | 11 |
| Education | $630.90 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $1,095.46 | 12 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $356.71 | 20 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $324.58 | 11 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $319.32 | 17 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $276.72 | 15 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $258.01 | 12 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $173.44 | 7 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $165.89 | 11 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $162.33 | 9 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $162.33 | 9 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $159.40 | 10 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $159.01 | 12 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $149.16 | 7 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $133.47 | 8 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $133.00 | 11 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $116.77 | 5 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $110.29 | 5 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $107.96 | 7 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $107.96 | 7 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $106.74 | 4 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $100.58 | 5 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $99.86 | 7 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, Merck Sharp & Dohme LLC | $98.65 | 4 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $96.30 | 5 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $95.22 | 4 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $95.22 | 4 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $94.74 | 5 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $92.22 | 4 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $86.81 | 4 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $84.11 | 4 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $78.01 | 3 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $75.92 | 4 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $71.06 | 4 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $71.06 | 4 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.67 | 3 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.67 | 3 | 2025 |
Source payment records
|
|||||
| TIVDAK Normalized: tivdak |
Biological | PFIZER INC. | $63.85 | 3 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $56.30 | 3 | 2025 |
Source payment records
|
|||||
| LUPRON DEPOT Normalized: lupron depot |
Drug | ABBVIE INC. | $53.22 | 3 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $50.15 | 4 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $49.11 | 3 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $48.81 | 3 | 2025 |
Source payment records
|
|||||
| LENVIMA Normalized: lenvima |
Drug | Eisai Inc., Merck Sharp & Dohme LLC | $48.56 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $48.02 | 2 | 2025 |
Source payment records
|
|||||
| ELEKTA MEDICAL LINEAR ACCELERATOR Normalized: elekta medical linear accelerator |
Device | Elekta, Inc. | $46.78 | 1 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $40.64 | 2 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $37.92 | 1 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $37.39 | 3 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $34.31 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $33.21 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC., Genmab U.S., Inc. | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $29.14 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $28.83 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| Ogivri Normalized: ogivri |
Drug | Biocon Biologics Inc | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| Fyarro Normalized: fyarro |
Drug | Fennec Pharmaceuticals, Inc. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| ROLVEDON Normalized: rolvedon |
Drug | Spectrum Pharmaceuticals Inc. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| Cellsearch Normalized: cellsearch |
Device | Menarini Silicon Biosystems, Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| ALUNBRIG Normalized: alunbrig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $20.75 | 3 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $20.75 | 3 | 2025 |
Source payment records
|
|||||
| Camcevi Normalized: camcevi |
Drug | ACCORD HEALTHCARE, INC. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INLYTA inlyta |
2025 | Inlyta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEYTRUDA keytruda |
2025 | Keytruda | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LUPRON DEPOT lupron depot |
2025 | Lupron Depot | 2024 | 13 | exact normalized | Medicare Part D |
| Nubeqa nubeqa |
2025 | Nubeqa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORGOVYX orgovyx |
2025 | Orgovyx | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 54 | exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 26 recipient NPIs · example record 1228888885 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Nubeqa open payments reported associated product |
CMS Open Payments — General Payments 24369 supporting records · 9557 recipient NPIs · example record 1225434669 |
Nubeqa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | OPDIVO open payments reported associated product |
CMS Open Payments — General Payments 1605 supporting records · 1197 recipient NPIs · example record 1184378433 |
Opdivo · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | OPDIVO open payments reported associated product |
CMS Open Payments — General Payments 20448 supporting records · 6494 recipient NPIs · example record 1184377705 |
Opdivo · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Tecentriq open payments reported associated product |
CMS Open Payments — General Payments 3585 supporting records · 2526 recipient NPIs · example record 1211488420 |
Tecentriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | KEYTRUDA open payments reported associated product |
CMS Open Payments — General Payments 46588 supporting records · 15767 recipient NPIs · example record 1237992210 |
Keytruda · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | INLYTA open payments reported associated product |
CMS Open Payments — General Payments 2646 supporting records · 1964 recipient NPIs · example record 1228795917 |
Inlyta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 16373 supporting records · 6981 recipient NPIs · example record 1228794230 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Xtandi | Enzalutamide | 71 | suppressed |
| Procrit | Epoetin Alfa | 67 | 23 |
| Venclexta | Venetoclax | 54 | 12 |
| Hydroxyurea | Hydroxyurea | 45 | 13 |
| Opdivo | Nivolumab | 40 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 37 | suppressed |
| Dexamethasone | Dexamethasone | 35 | 16 |
| Darzalex Faspro | Daratumumab-Hyaluronidase-Fihj | 34 | suppressed |
| Revlimid | Lenalidomide | 33 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 32 | suppressed |
| Orgovyx | Relugolix | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Prednisone | Prednisone | 28 | suppressed |
| Bortezomib | Bortezomib | 27 | suppressed |
| Gabapentin | Gabapentin | 27 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Kyprolis | Carfilzomib | 21 | suppressed |
| Letrozole | Letrozole | 21 | suppressed |
| Udenyca Autoinjector | Pegfilgrastim-Cbqv | 21 | suppressed |
| Xgeva | Denosumab | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Inlyta | Axitinib | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 17 |
| Zoledronic Acid | Zoledronic Acid | 20 | suppressed |
| Bicalutamide | Bicalutamide | 19 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Promacta | Eltrombopag Olamine | 16 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Sprycel | Dasatinib | 15 | suppressed |
| Keytruda | Pembrolizumab | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 11 |
| Lupron Depot | Leuprolide Acetate | 13 | 12 |
| Tecentriq | Atezolizumab | 13 | suppressed |
| Lenalidomide | Lenalidomide | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Pemetrexed Disodium | Pemetrexed Disodium | 12 | suppressed |
| Yervoy | Ipilimumab | 12 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 11 | suppressed |
| Nubeqa | Darolutamide | 11 | suppressed |
| Pomalyst | Pomalidomide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,216.05 · 241 records | Novartis Pharmaceuticals Corporation | ADCETRIS, AKEEGA, ALUNBRIG, BALVERSA, BESREMI, BLENREP, BOSULIF, BRAFTOVI, BRUKINSA, Camcevi, Cellsearch, DARZALEX, DATROWAY, ELEKTA MEDICAL LINEAR ACCELERATOR, ELREXFIO, ENHERTU, EPKINLY, ERLEADA, FRUZAQLA, Fabhalta, Fyarro, IBRANCE, ICLUSIG, IMBRUVICA, INJECTAFER, INLYTA, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LENVIMA, LORBRENA, LUPRON DEPOT, LUTATHERA, MEKTOVI, MI CANCER SEEK, MONOFERRIC, Nubeqa, OJJAARA, OPDUALAG, ORGOVYX, Ogivri, Onivyde, Optune Lua (NovoTTF-200T), Orserdu, PADCEV, PLUVICTO, PROVENGE, REBLOZYL, ROLVEDON, RYBREVANT, RYTELO, SARCLISA, TAGRISSO, TALVEY, TALZENNA, TECVAYLI, TEVIMBRA, TIVDAK, TUKYSA, Trodelvy, VENCLEXTA, VERZENIO, VYEPTI, Vonjo, WAYRILZ, WELIREG, XPOVIO, XT CDX, XTANDI, Xofigo, ZEJULA, ZYNLONTA | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Inlyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error